Charles River is expanding our team. Some of our exciting careers include:
I need a Charles River expert for technical assistance, customer service or sales support.
*indicates a required field.
The information you provided will be kept confidential.
juil. 29
Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. (NYSE: WX) to terminate their previously announced acquisition agreement. The Company also announced that its Board of Directors has authorized a new $500 million stock repurchase program.
juil. 21
When animals are used in research, the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International works with institutions and researchers to serve as a bridge between progress and animal well-being. This coordination is accomplished through the voluntary AAALAC accreditation and assessment process, in which organizations demonstrate that they not only meet the minimum standards required by law, but also go the extra step to achieve excellence in animal care and use. Recently, the Charles River facility in Margate, UK, which breeds research models and provides related services, received full AAALAC accreditation. Charles River is the first and only commercial small animal breeder in the UK to receive AAALAC accreditation.
juil. 13
Genetic toxicology testing is a key element in the development of pharmaceuticals, agrochemicals and chemicals. Formal GLP testing is required as part of the safety evaluation of all compounds; however, many companies perform non-GLP genetic toxicology screening very early to avoid expensive failures later. At this point, compound availability is normally limited, so it is important to minimize usage while ensuring the most accurate predictivity of the outcome of the eventual GLP assays. Charles River now offers in vitro genetic toxicology screening assays in which compound requirements can be as little as 10 mg: Bluescreen HC, Bluescreen HC S9 and µAmes.
sept. 13–sept. 15
The Biotech symposium is designed to provide insights into nonclinical development of biologics, Specific topics that will be covered include: Safety Pharmacology of Therapeutic Proteins; Impact of Immunomodulatory Agents on Host Resistance; New Paradigms for Predicting Cancer Risks Posed by Immunosuppressive Drugs; PK/PD Modeling: Extrapolating from Animal Data into First-in-Human Dose; and DART Programs for Biotherapeutics: Study Designs, Challenges and Regulatory Influences. In addition to the symposium, we will offer a workshop on endemic diseases and micro-flora as they relate to toxicology on September 12th.
The Health & Safety Officer provides support to the Safety Manager in all matters relating to the provision of H&S. Major responsibilities of this position include: providing assistance to local managers with assessments and other practical requirements as necessary under H&S legislation; assisting in the operation, development and organisation of safety and health monitoring schemes; assisting in the development and monitoring of systems for the control of all operations involving the use of radioactive materials in accordance with current legislation; undertaking incident investigations as necessary; serving as a liaison with the Occupation Health Service and internal and external Enforcing Authorities as required; carrying out regular H&S audits; and assisting in staff safety training.
The Clinical Pathology Analyst is responsible for undertaking routine and specialised analyses in clinical chemistry and haematology as well as for assessing and reporting clinical pathology data. Other tasks include monitoring the performance of assays and equipment with internal and external quality control, maintaining legible and permanent records of all results obtained together with relevant supporting data, and participating in development of new techniques and services.